Incanthera (AQSE:INC) Receivables Turnover : 0.00 (As of Sep. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Incanthera Receivables Turnover?

The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Incanthera's Revenue for the six months ended in Sep. 2023 was £0.00 Mil. Incanthera's average Accounts Receivable for the six months ended in Sep. 2023 was £0.03 Mil.

Incanthera Receivables Turnover Historical Data

The historical data trend for Incanthera's Receivables Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Incanthera Receivables Turnover Chart

Incanthera Annual Data

Trend

Mar20

Mar21

Mar22

Mar23

Receivables Turnover

Incanthera Semi-Annual Data
	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Receivables Turnover	Get a 7-Day Free Trial			-	-	-	-	-

Competitive Comparison of Incanthera's Receivables Turnover

For the Biotechnology subindustry, Incanthera's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Incanthera's Receivables Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Incanthera's Receivables Turnover distribution charts can be found below:

* The bar in red indicates where Incanthera's Receivables Turnover falls into.

Incanthera Receivables Turnover Calculation

Receivables Turnover measures the number of times a company collects its average accounts receivable balance.

Incanthera's Receivables Turnover for the fiscal year that ended in Mar. 2023 is calculated as

	Receivables Turnover (A: Mar. 2023 )
=	Revenue	/	Average Total Inventories
=	Revenue (A: Mar. 2023 )	/ (	(Accounts Receivable (A: Mar. 2022 )	+	Accounts Receivable (A: Mar. 2023 ))	/	count )
=	0	/ (	(0	+	0)	/	1 )
=	0	/	0
=	N/A

Incanthera's Receivables Turnover for the quarter that ended in Sep. 2023 is calculated as

	Receivables Turnover (Q: Sep. 2023 )
=	Revenue	/	Average Total Inventories
=	Revenue (Q: Sep. 2023 )	/ (	(Accounts Receivable (Q: Mar. 2023 )	+	Accounts Receivable (Q: Sep. 2023 ))	/	count )
=	0	/ (	(0	+	0.033)	/	1 )
=	0	/	0.033
=	N/A

Incanthera (AQSE:INC) Receivables Turnover Explanation

An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.

Incanthera Receivables Turnover Related Terms

Thank you for viewing the detailed overview of Incanthera's Receivables Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.

Incanthera (AQSE:INC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Incanthera PLC (AQSE:INC) » Definitions » Receivables Turnover

Comparable Companies

Traded in Other Exchanges

N/A

Address

76 King Street, Manchester, GBR, M2 4NH

Website

http://www.incanthera.com

Incanthera PLC is a specialist dermatology and oncology company focused on transforming cancer treatment by creating environments in which cancer cannot survive. It identifies and develops solutions to current clinical, commercially relevant unmet needs, utilising a new technology. The company's current products are Sol, EP0015, Equin and Duo-C. The company has one segment, namely the development of pharmaceutical products all within the United Kingdom.

Incanthera (AQSE:INC) Headlines

No Headlines